Business
ONWARD Medical Successfully Raises over EUR 40 Million in Capital Increase
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Transaction includes EUR 25.0M investment from EQT Life SciencesStron
About this update from Onward Medical N.v.
[{"type":"image","alt":"ONWARD Medical NV","displaySize":"","headline":null,"caption":"ONWARD Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/ff435d5a4437f6b633ad80dab68096d0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k5H42ENtwWiIFVl5nWlEJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMA--/https://media.zenfs.com/en/globenewswire.com/ff435d5a4437f6b633ad80dab68096d0","width":300,"height":150}},"lazy":false},{"type":"text","content":"NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.","length":295,"tagName":"p"},{"type":"text","content":"THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)","length":134,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Transaction includes EUR 25.0M investment from EQT Life Sciences","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong additional support from high-quality, long-only and sector specialist investors","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash runway now extends into Q1 2028","length":36,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":186,"olType":false},{"type":"text","content":"EINDHOVEN, the Netherlands, April 16, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces that it successfully raised an amount of EUR 40.6M in gross proceeds by way of an accelerated bookbuild offering through a private placement with institutional investors of 13,520,254 new ordinary shares (the “Private Placement” and such shares the “New Shares”) via the Joint Bookrunners (as defined below). The New Shares were offered at an issue price of EUR 3.00 per share (the “Issue Price”). The Issue Price was determined by the Company’s pricing committee.","length":777,"tagName":"p"},{"type":"text","content":"The succ...